Deals
Valeant Is Said to Agree to Buy Salix for $10.1 Billion
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. agreed to buy Salix Pharmaceuticals Ltd. for about $10.1 billion, a person with knowledge of the matter said, to add gastrointestinal drugs to its stable of offerings.
Valeant will pay $158 a share in cash for Salix, the person said, asking not to be identified because the company hasn’t announced the deal. Salix shares rose $7.11 to $157.85 on Friday, almost completely eliminating any premium in the purchase price.